Iloprost in Preventing Lung Cancer in Former Smokers

Phase 1 Completed 34 enrolled National Cancer Institute (NCI)

Non-randomizedParallel-groupDouble-blindPrevention

Summary

This phase I trial studies the side effects and best dose of iloprost compared with a placebo in preventing lung cancer in former smokers. Chemoprevention is the use of drugs to keep cancer from forming or coming back. Inhaled iloprost may help prevent lung cancer from forming in patients who used to smoke and who have been found to have abnormal cells in their mucus.

Timeline

Start: 2015-11-05
Primary completion: 2020-03-05
Completion: 2023-08-30

Outcome

Results reported · no primary-endpoint met/missed verdict (typical of a dose-finding / safety study)

paper The trial was not powered to detect histologic response and none was found. PMID 37711198 ↗

Publications

Miller YE, Ghosh M, Merrick DT, Kubala B, Szabo E, Bengtson L, Kocherginsky M, Helenowski IB, Benante K, Schering T, Kim J, Kim H, Ha D, Bergan RC, Khan SA, Keith RL. Phase Ib trial of inhaled iloprost for the prevention of lung cancer with predictive and response biomarker assessment. Front Oncol. 2023 Aug 30;13:1204726. doi: 10.3389/fonc.2023.1204726. eCollection 2023.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Iloprost	Other / unclassified	—	Inhaled